Poor Liver Function Tied to Worse Survival Among HCC Patients on ICIs
Patients with advanced hepatocellular carcinoma have worse outcomes on immune checkpoint inhibitor therapy if they have worse liver function, a meta-analysis suggests.
Diagnosis & Disease Information
First-Line Camrelizumab Plus Rivoceranib Outperforms Sorafenib in Unresectable HCC
Combination treatment with camrelizumab and rivoceranib is more effective than sorafenib monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma, phase 3 data suggest.
Rivoceranib Plus Camrelizumab Under Review for Unresectable Hepatocellular Carcinoma
A regulatory decision is expected on May 16, 2024.
IARC Declares Aspartame a Possible Carcinogen
Aspartame may be carcinogenic, according to the World Health Organization’s International Agency for Research on Cancer.
Sex Hormones Linked to Risk of Gastrointestinal Cancers
Higher levels of certain sex hormones are associated with an increased risk of some gastrointestinal cancers, a meta-analysis suggests.
Results With Atezolizumab and Bevacizumab May Prove Practice-Changing for HCC
Adjuvant treatment with atezolizumab and bevacizumab prolongs recurrence-free survival, when compared with active surveillance, in patients with hepatocellular carcinoma, a phase 3 study suggests.
Diets Promoting Inflammation, Hyperinsulinemia May Increase Risk of HCC
Diets that promote inflammation and hyperinsulinemia may increase the risk of hepatocellular carcinoma, a study suggests.
Cancer Patients May Be Treated With Drugs That Provide No Benefit
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Benefit Seen With SBRT Before Sorafenib in Advanced HCC
SBRT prior to sorafenib improved outcomes, compared with sorafenib alone, in a phase 3 trial of patients with advanced hepatocellular carcinoma.
Combining TACE and Sorafenib Improves Survival in HCC With PVTT
The addition of transarterial chemoembolization to adjuvant sorafenib improved outcomes for patients with hepatocellular carcinoma and portal vein tumor thrombosis in a phase 2 trial.
- Loading...
Loading...
Next post in ASCO GI 2023
Loading... 
Loading...